As of 2026-03-05, the EV/EBITDA ratio of Novartis AG (NOVN.SW) is 10.24. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NOVN.SW's latest enterprise value is 288,129.20 mil CHF. NOVN.SW's TTM EBITDA according to its financial statements is 28,135.00 mil CHF. Dividing these 2 quantities gives us the above NOVN.SW EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 8.9x - 11.0x | 10.1x |
| Forward P/E multiples | 11.4x - 14.3x | 11.9x |
| Fair Price | 81.57 - 104.22 | 89.94 |
| Upside | -36.1% - -18.4% | -29.6% |
| Date | EV/EBITDA |
| 2026-03-04 | 10.44 |
| 2026-03-03 | 10.34 |
| 2026-03-02 | 10.61 |
| 2026-02-27 | 10.65 |
| 2026-02-26 | 10.47 |
| 2026-02-25 | 10.60 |
| 2026-02-24 | 10.58 |
| 2026-02-23 | 10.46 |
| 2026-02-20 | 10.35 |
| 2026-02-19 | 10.35 |
| 2026-02-18 | 10.41 |
| 2026-02-17 | 10.49 |
| 2026-02-16 | 10.35 |
| 2026-02-13 | 10.25 |
| 2026-02-12 | 10.15 |
| 2026-02-11 | 10.09 |
| 2026-02-10 | 9.94 |
| 2026-02-09 | 9.88 |
| 2026-02-06 | 9.86 |
| 2026-02-05 | 9.81 |
| 2026-02-04 | 9.76 |
| 2026-02-03 | 9.63 |
| 2026-02-02 | 9.65 |
| 2026-01-30 | 9.46 |
| 2026-01-29 | 9.43 |
| 2026-01-28 | 9.43 |
| 2026-01-27 | 9.60 |
| 2026-01-26 | 9.55 |
| 2026-01-23 | 9.53 |
| 2026-01-22 | 9.49 |
| 2026-01-21 | 9.44 |
| 2026-01-20 | 9.43 |
| 2026-01-19 | 9.53 |
| 2026-01-16 | 9.53 |
| 2026-01-15 | 9.45 |
| 2026-01-14 | 9.56 |
| 2026-01-13 | 9.38 |
| 2026-01-12 | 9.40 |
| 2026-01-09 | 9.41 |
| 2026-01-08 | 9.39 |
| 2026-01-07 | 9.38 |
| 2026-01-06 | 9.22 |
| 2026-01-05 | 9.00 |
| 2025-12-30 | 9.08 |
| 2025-12-29 | 9.10 |
| 2025-12-23 | 9.12 |
| 2025-12-22 | 9.01 |
| 2025-12-19 | 9.00 |
| 2025-12-18 | 8.94 |
| 2025-12-17 | 8.96 |